Advertisement

A relapsing case of pulmonary–renal syndrome after a sequential rise in MPO–ANCA and anti-GBM antibodies

  • Akiko Hoshino
  • Toru SakairiEmail author
  • Ken Kayakabe
  • Masahito Baba
  • Masayasu Ando
  • Hayato Kimura
  • Rena Motohashi
  • Yoshihisa Nojima
  • Keiju Hiromura
Case Report
  • 22 Downloads

Abstract

A 69-year-old woman who presented with severe renal dysfunction and diffuse alveolar hemorrhage was diagnosed with pulmonary–renal syndrome (PRS) based on the coexistence of serum myeloperoxidase (MPO)–antineutrophil cytoplasmic antibodies (ANCA) and anti-glomerular basement membrane (GBM) antibodies (Ab). Hemodialysis was started; plasma exchange and intravenous methylprednisolone pulse therapy were administered followed by oral prednisolone administration. Pulmonary hemorrhage decreased; however, renal dysfunction persisted. On maintenance hemodialysis and prednisolone therapy, MPO–ANCA and anti-GBM Ab became negative at 4 and 10 months, respectively; thereafter, they became positive again at 18 and 35 months, respectively. At 36 months, there was relapse of pulmonary hemorrhage. Plasma exchange and intravenous methylprednisolone pulse therapy were administered; pulmonary hemorrhage ceased, and both antibodies became negative. It is known that PRS cases that are double positive for ANCA and anti-GBM Ab occasionally relapse after remission, and, even though they are double positive at initial diagnosis, most relapses occur with reappearance or re-elevation of ANCA but with absence of anti-GBM-Ab. Therefore, this was a rare relapsing case that presented with double-positive serology. Further, our observation that the reappearance of ANCA preceded that of anti-GBM-Ab suggests that ANCA contribute to the reproduction of anti-GBM Ab.

Keywords

Anti-GBM antibody MPO–ANCA Pulmonary–renal syndrome Rapidly progressive glomerulonephritis Relapse 

Notes

Acknowledgements

This case report was presented in the 18th international vasculitis and ANCA Workshop (Tokyo, Japan, 2017).

Compliance with ethical standards

Conflict of interest

Authors declare no conflict of interest.

Informed consent

Informed consent was obtained from the patient for publication of this case report.

References

  1. 1.
    Niles JL, Bottinger EP, Saurina GR, Kelly KJ, Pan G, Collins AB, et al. The syndrome of lung hemorrhage and nephritis is usually an ANCA-associated condition. Arch Intern Med. 1996;156(4):440–5.CrossRefGoogle Scholar
  2. 2.
    Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65(1):1–11.  https://doi.org/10.1002/art.37715.CrossRefGoogle Scholar
  3. 3.
    McAdoo SP, Tanna A, Hruskova Z, Holm L, Weiner M, Arulkumaran N, et al. Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients. Kidney Int. 2017;92(3):693–702.  https://doi.org/10.1016/j.kint.2017.03.014.CrossRefGoogle Scholar
  4. 4.
    Rutgers A, Slot M, van Paassen P, van Breda Vriesman P, Heeringa P, Tervaert JW. Coexistence of anti-glomerular basement membrane antibodies and myeloperoxidase-ANCAs in crescentic glomerulonephritis. Am J Kidney Dis. 2005;46(2):253–62.  https://doi.org/10.1053/j.ajkd.2005.05.003.CrossRefGoogle Scholar
  5. 5.
    Levy JB, Hammad T, Coulthart A, Dougan T, Pusey CD. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int. 2004;66(4):1535–40.  https://doi.org/10.1111/j.1523-1755.2004.00917.x.CrossRefGoogle Scholar
  6. 6.
    Short AK, Esnault VL, Lockwood CM. Anti-neutrophil cytoplasm antibodies and anti-glomerular basement membrane antibodies: two coexisting distinct autoreactivities detectable in patients with rapidly progressive glomerulonephritis. Am J Kidney Dis. 1995;26(3):439–45.CrossRefGoogle Scholar
  7. 7.
    Zhao J, Yang R, Cui Z, Chen M, Zhao MH, Wang HY. Characteristics and outcome of Chinese patients with both antineutrophil cytoplasmic antibody and antiglomerular basement membrane antibodies. Nephron Clin Pract. 2007;107(2):c56–62.  https://doi.org/10.1159/000107803.CrossRefGoogle Scholar
  8. 8.
    Jennette JC. Rapidly progressive crescentic glomerulonephritis. Kidney Int. 2003;63(3):1164–77.  https://doi.org/10.1046/j.1523-1755.2003.00843.x.CrossRefGoogle Scholar
  9. 9.
    Alchi B, Griffiths M, Sivalingam M, Jayne D, Farrington K. Predictors of renal and patient outcomes in anti-GBM disease: clinicopathologic analysis of a two-centre cohort. Nephrol Dial Transpl. 2015;30(5):814–21.  https://doi.org/10.1093/ndt/gfu399.CrossRefGoogle Scholar
  10. 10.
    DE Zoysa Jr., Taylor D, Thein H, Yehia M. Incidence and features of dual anti-GBM-positive and ANCA-positive patients. Nephrology (Carlton). 2011;16(8):725-9. https://doi.org/10.1111/j.1440-1797.2011.01484.x.CrossRefGoogle Scholar
  11. 11.
    Cui Z, Zhao J, Jia XY, Zhu SN, Zhao MH. Clinical features and outcomes of anti-glomerular basement membrane disease in older patients. Am J Kidney Dis. 2011;57(4):575–82.  https://doi.org/10.1053/j.ajkd.2010.09.022.CrossRefGoogle Scholar
  12. 12.
    Levy JB, Turner AN, Rees AJ, Pusey CD. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med. 2001;134(11):1033–42.CrossRefGoogle Scholar
  13. 13.
    Srivastava A, Rao GK, Segal PE, Shah M, Geetha D. Characteristics and outcome of crescentic glomerulonephritis in patients with both antineutrophil cytoplasmic antibody and anti-glomerular basement membrane antibody. Clin Rheumatol. 2013;32(9):1317–22.  https://doi.org/10.1007/s10067-013-2268-5.CrossRefGoogle Scholar
  14. 14.
    Levy JB, Lachmann RH, Pusey CD. Recurrent goodpasture's disease. Am J Kidney Dis. 1996;27(4):573–8.CrossRefGoogle Scholar
  15. 15.
    Serratrice J, Chiche L, Dussol B, Granel B, Daniel L, Jego-Desplat S, et al. Sequential development of perinuclear ANCA-associated vasculitis and anti-glomerular basement membrane glomerulonephritis. Am J Kidney Dis. 2004;43(3):e26–30.CrossRefGoogle Scholar
  16. 16.
    Gallagher JL, Sinha S, Reeve R, Kalra PA. Importance of checking anti-glomerular basement membrane antibody status in patients with anti-neutrophil cytoplasmic antibody-positive vasculitis. Postgrad Med J. 2008;84(990):220–2.  https://doi.org/10.1136/pgmj.2007.062752.CrossRefGoogle Scholar
  17. 17.
    Yang R, Hellmark T, Zhao J, Cui Z, Segelmark M, Zhao MH, et al. Antigen and epitope specificity of anti-glomerular basement membrane antibodies in patients with Goodpasture disease with or without anti-neutrophil cytoplasmic antibodies. J Am Soc Nephrol. 2007;18(4):1338–433.  https://doi.org/10.1681/ASN.2006111210.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2019

Authors and Affiliations

  1. 1.Division of Rheumatology and NephrologyMaebashi Red Cross HospitalMaebashiJapan
  2. 2.Department of Nephrology and RheumatologyGunma University Graduate School of MedicineMaebashiJapan

Personalised recommendations